Safety & Interactions

Safety profile, CYP interactions, anticoagulant cautions, and monitoring considerations for Boswellia in oncology

Boswellia has a generally favourable safety profile, but it still needs proper review in oncology because of CYP interactions, anticoagulant questions, and active-treatment timing issues.

General tolerability

generally well tolerated in clinical trials
higher doses are usually associated with mild GI symptoms rather than severe toxicity
no strong QT or cardiac-toxicity signal has emerged

Main cautions

CYP interactions

Boswellia may affect several CYP pathways relevant to cancer care, including tamoxifen-related CYP2D6 discussion and taxane- or corticosteroid-related CYP3A4 discussion.

How to interpret interaction evidence

Cell and laboratory findings can identify a possible interaction. They do not confirm the same effect occurs in people.

Read interaction claims alongside human pharmacokinetic and clinical evidence. See Drug Interaction Evidence and CYP Enzymes for the evidence hierarchy and practical questions to ask.

Anticoagulant and antiplatelet caution

There is a theoretical mild blood-thinning concern, so extra caution is reasonable in people on warfarin, aspirin, clopidogrel, or with bleeding-risk states.

Immunosuppressant context

Because Boswellia can influence inflammatory signalling and may have immunoregulatory effects, specialist review is sensible in patients on transplant or heavy immunosuppressive regimens.

Practical takeaway

Boswellia is not a high-toxicity compound in routine use, but it still deserves the same respect as any active adjunct when a person is on chemotherapy, radiotherapy, endocrine therapy, steroids, or anticoagulants.

Interaction checkers

Memorial Sloan Kettering — About Herbs Database
https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs
Drugs.com Interaction Checker
https://www.drugs.com/drug_interactions.html

Key References

Boswellia serrata: drug interactions
https://www.rxlist.com/supplements/boswellia.htm

The anti-proliferative effects of a frankincense extract in a window of opportunity Phase Ia clinical trial for patients with breast cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC10959833/

NCCIH Boswellia overview
https://www.nccih.nih.gov/health/boswellia

Jump to another Boswellia page

Core pages

Mechanism deep dives

Practical pages

Cancer-type pages

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.